1237MO SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) – A multicenter single-arm phase II trial
| Autor: | Rothschild, S.I., Zippelius, A., Eboulet, E.I., Savic Prince, S., Betticher, D., Bettini, A., Früh, M., Joerger, M., Britschgi, C., Peters, S., Mark, M.T., Ochsenbein, A.F., Janthur, W-D., Waibel, C., Mach, N., Gonzalez, M., Froesch, P.R., Godar, G., Rusterholz, C., Pless, M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S803-S804 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|